<DOC>
	<DOCNO>NCT02825420</DOCNO>
	<brief_summary>Non-interventional , multicenter , prospective , European study describe effectiveness trabectedin + PLD treatment relapse ovarian cancer ( ROC ) patient accord SmPC regardless previous use antiangiogenic drug</brief_summary>
	<brief_title>Non-interventional European Study Trabectedin + PLD Treatment Relapsed Ovarian Cancer ( ROC ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Women age 18 year old . Presence platinumsensitive relapse ovarian cancer . Treatment treat indication accord local label SmPC reimbursement trabectedin PLD treatment . Prior treatment minimum 1 cycle trabectedin + PLD accord SmPC inclusion study , 3 previous treatment line . Written inform consent indicate patient understand purpose procedure willing participate study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>